Can we identify metabolically healthy but obese individuals (MHO)?
Can we identify metabolically healthy but obese individuals (MHO)?
复制标题
DOI：
10.1016/s1262-3636(07)70156-8
复制
发表时间：
2004-12-01
影响因子：
7.2
通讯作者：
Rabasa-Lhoret, R
中科院分区：
文献类型：
--
作者：
Karelis, A;Brochu, M;Rabasa-Lhoret, R
目的：在文献中描述了一个称为代谢健康但肥胖（MHO）的肥胖个体的独特子集。然而，没有商定的方法来识别MHO个体用于研究方案或临床实践。因此，我们研究了一个大型队列的肥胖老年妇女，试图开发第一套临床标志物，可以识别MHO individuals.Methods：我们研究了154肥胖绝经后妇女（年龄：57.0 +/- 5.3岁和BMI：34.3 +/- 5.5 kg/m2）。MHO个体的选择标准部分基于国家胆固醇教育计划的成人治疗小组III报告（ATP III）的血脂谱（甘油三酯：小于或等于1.7 mmol/l，总胆固醇：小于或等于5.2 mmol/l，HDL-胆固醇：1.3 mmol/l和LDL-胆固醇：小于或等于2.6 mmol/l）和Brochu等人（2001）的胰岛素敏感性研究（HOMA小于或等于1.95）。当5个标准中有4个符合时，我们建议可以诊断MHO个体。结果：根据所提出的标准，154名绝经后妇女中有19名（12.3%）被确定为MHO。通过设计，MHO个人表现出良好的血脂和较高的胰岛素敏感性values.Conclusion：我们建议一套潜在的新的临床标志物，以确定MHO个人。识别MHO个体可能对治疗性医疗决策，研究方案和医学教育中的主题特征具有重要意义。
Objectives: A unique subset of obese individuals termed, Metabolically Healthy but Obese (MHO), has been described in the literature. However, there is no agreed upon method to identify MHO individuals for research protocols or in clinical practice. Therefore, we examined a large cohort of obese older women to attempt to develop a first set of clinical markers that may identify MHO individuals.Methods: We studied 154 obese postmenopausal women (age: 57.0 +/- 5.3 years and BMI: 34.3 +/- 5.5 kg/m(2)). Selection criteria for MHO individuals were partially based on the National Cholesterol Education Program's Adult Treatment Panel III report (ATP III) for lipid profiles (triglycerides: less than or equal to 1.7 mmol/l, total cholesterol: less than or equal to 5.2 mmol/l, HDL-cholesterol: 1.3 mmol/l and LDL-cholesterol: less than or equal to 2.6 mmol/l) and from the study of Brochu et al. (2001) for insulin sensitivity (HOMA less than or equal to 1.95). When 4 out of 5 criteria are met, we suggest that a diagnosis of the MHO individual could be made.Results: Based on the proposed criteria, 19 out of 154 (12.3%) postmenopausal women subjects were identified as MHO. By design, MHO individuals showed a favourable lipid profile and higher insulin sensitivity values.Conclusion: We suggest a potential new set of clinical markers to identify MHO individuals. Identifying MHO individuals could have important implications for therapeutic medical decision making, subject characterization in research protocols and in medical education.